You Are Here: Home > About Arthritis > Arthritis in the News > AbbVie Receives Health Canada Approval of new oral RA Medication RINVOQ® (upadacitinib)

AbbVie Receives Health Canada Approval of new oral RA Medication RINVOQ® (upadacitinib)

Inflammatory forms of arthritis can be aggressive, and in the absence of a cure, medication can play a vital role in the treatment plan,. Patients and their physicians need access to a variety of treatment options. The Arthritis Society welcomes the approval of new treatments that expand the options available to Canadians living with arthritis.Back to News